A method for the treatment of paroxysmal nodal tachycardia

 

(57) Abstract:

The invention relates to medicine, particularly cardiology, and for the treatment of paroxysmal supraventricular tachycardia. For this intravenous Relanium in average therapeutic dose, and then one of the drugs agonists adenosine receptors, for example, adenosine or ATP. The method allows to reduce complications of treatment and the possibility of relapse.

The invention relates to medicine, specifically to the section of cardiology, and for the treatment of paroxysmal nodal tachycardia.

Of pharmacological agents used for edema paroxysmal nodal tachycardia, the drugs of choice are agonists of adenosine receptors adenosine and ATP [2, 3]. Intravenous bolus causes a short delay, in some cases, prior to the blockade, of the proceedings, which is able to interrupt mechanism gay-entre in the AV connection [2].

However, despite the useful properties of drugs, the practice is to limit their use, due to the relatively frequent adverse effects [3].

Poor tolerability of patients in Balk the emergence of a patients death anxiety and agitation. Hypersympathicotonia, and without accompanying paroxysmal arrhythmias may further exacerbate cardiac symptoms and to play a role in the maintenance of the arrhythmia and its recurrence.

It is known that in the preparation of patients for anesthesia or local anesthesia to reduce psihoemotsianalnogo voltage, warnings, pathological reflexes, apply special pharmacological preparation - sedation [1] . For this purpose use narcotic analgesics, sedatives, anticholinergic [1].

The purpose of the invention: prevention and elimination of side effects of agonists of adenosine receptors (adenosine, ATP), and improving the effectiveness of treatment in patients with paroxysmal nodal tachycardia.

The proposed method differs in that prior to the introduction of adenosine (or adenosine triphosphate (ATP) intravenously injected 2 ml of 0.5% solution Relanium.

Example 1. Patient M. , 32, For the past 10 years disturb rare (1-2 times per year), mild and occur without apparent cause bouts of palpitations. Normal rhythm was restored self - straining effort. For health care has never been addressed and were not surveyed. Latter standing moderate severity, due to hemodynamic disturbances. The patient is frightened, somewhat excited. Skin pale, forehead cold sweat. The fingers are cold to the touch, moderate acrocyanosis. BH 18 per minute. Auscultation - heart sounds are clear, correct rhythm, tachycardia with a heart rate over 140 beats per minute. HELL 90/60-80/60 mm RT.article.

ECG - signs of nodal tachycardia. Rhythm nakanosawa, correct. The QRS complex is narrow. Prong P is not defined. The heart rate of 180 per minute.

Intravenous introduced in 2.0 ml of 0.5% R-RA Relanium and with the onset of sedative effect (drug-induced sleep) - inkjet 1,0 1% of ATP. 15, from the moment of introduction of ATP, developed asystole. Restore cardiac activity occurred at 23 C. the Total duration of asystole was 8 C.

ECG sinus rhythm correct. HR 80 in minutes

After restoring the rhythm, sick in the mind, is a bit laggy. The period of asystole moved painlessly. She feels good. In addition to moderate weakness, no complaints. AD - 105/70-100/70 mm RT.article Arrhythmia not had anticipated.

Use Relanium in combination with ATP or adenosine in paroxysmal nodal tachycardia is more human the TB recurrence of the arrhythmia.

Sources of information

1. Great medical encyclopedia - 3rd ed. - M.: "Soviet encyclopedia", 1983, volume 21, S. 36; volume 16, S. 145.

2. Blizzard Century. And. Handbook on clinical pharmacology of cardiovascular drugs): Malpractice, 1996, S. 453-454.

3. Ruxin centuries Emergency cardiology. - SPb.: Nevsky dialect, 1997, S. 110.

A method for the treatment of paroxysmal nodal tachycardia by introducing agonists adenosine receptors, wherein the pre-intravenously injected Relanium.

 

Same patents:

The invention relates to new substituted benzosulfimide or timesaving formula I and their pharmaceutically acceptable salts, method of production thereof, containing pharmaceutical composition and method of reception

The invention relates to new substituted benzosulfimide or-thiourea of the formula I and their pharmaceutically acceptable salts, possess antiarrhythmic activity and activity to prevent sudden, caused by arrhythmia death from cardiac arrest, the way they are received, containing pharmaceutical composition and method of reception

The invention relates to medicine, in particular for intensive therapy of myocardial infarction, complicated rhythm as ventricular arrythmia

The invention relates to medicine and relates to the use of cannabinoid receptor R-(+)-methanandamide as antiarrhythmic agent

The invention relates to medicine, specifically to 2-(2'-hydroxy-2'-substituted)ethyl-1,2,3,4-tetrahydropyrrolo[1,2-a] pyrazines or their fumarate with antiarrhythmic and antiischemic activity

The invention relates to new guanidinium heterocyclic compounds of the formula (I), where R1denotes H, alkyl or is absent when R1missing link (a) is a double bond, D represents CR2, R2selected from H, alkyl, halogen, or, when is a CR3D can be N, denotes NR9, CR3=CR8, CR3, S, where R9denotes H, alkyl, alkenyl or quinil and where R3and R8selected from H, alkyl, alkenyl, quinil or cyano, R4, R5, R6each independently selected from H, alkyl, alkenyl, quinil, cyano, halogen or NH-C(= NR10)OTHER11(guanidine), R10and R11selected from H, methyl and ethyl, and where only one of R1, R5and R6is guanidines, R7selected from H, alkyl, alkenyl, quinil and halogen

The invention relates to phenylselenenyl guanidium alkenylboronic acid of the formula (I)

< / BR>
where T means

< / BR>
moreover, R(A) denotes hydrogen, fluorine, chlorine, bromine, iodine, CN, IT, OR(6), (C1-C4)-alkyl, Or(CH2)aCbF2b+l, (C3-C8-cycloalkyl or NR(7)R(8); where

r denotes zero or 1;

a represents zero, 1, 2, 3 or 4;

b means 1, 2, 3 or 4;

R(6) means (C1-C4)-alkyl, (C1-C4)-perfluoroalkyl, (C3-C6)-alkenyl, (C3-C8-cycloalkyl, phenyl or benzyl;

and the phenyl nucleus is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF3, methyl, metoxygroup and NR(9)R(10);

where

R(9) and R(10) mean hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;

R(7) and R(8) independently of one another are specified for R(6) the value, or

R(7) and R(8) together mean 4 or 5 methylene groups, of which one CH2group can be replaced by oxygen, sulfur, NH, N-CH3or N-benzyl;

R(B) R(C) and R(D) independently from each other are specified for R(A) mn is od CN, OR(12), (C1-C8)-alkyl, Op(CH2)fCgF2g+l, (C3-C8-cycloalkyl or (C1-C9)heteroaryl;

R denotes zero or 1;

f is zero, 1, 2, 3 or 4;

g means 1, 2, 3, 4, 5, 6, 7 or 8;

R(12) means (C1-C8)-alkyl, (C1-C4)-perfluoroalkyl, (C3-C8)-alkenyl, (C3-C8-cycloalkyl, phenyl or benzyl,

and the phenyl nucleus is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF3, methyl, metoxygroup and NR(13)R(14); where

R(13) and R(14) denote hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;

R(E) has independently specified for R(F) value;

R(1) independently has a specified T value; or

R(1) means hydrogen, -OkCmH2m+l, -On(CH2)pCqF2q+1, fluorine, chlorine, bromine, iodine, CN, -(C= O)-N=C(NH2)2, -SOrR(17), -SOr2NR(31)R(32), -Ou(CH2)vWITH6H5, -Ou2-(C1-C9-heteroaryl or-Su2-(C1-C9-heteroaryl;

k is zero or 1;

m means zero, 1, 2, 3, 4, 5, 6, 7 or 8;

n denotes zero or 1;

p denotes zero, 1, 2, 3 or 4;

q is 1, 2,with hydrogen, (C1-C8)-alkyl or (C1-C8)-perfluoroalkyl or

R(31) R(32) together form a 4 or 5 methylene groups, of which one CH2group can be replaced by oxygen, sulfur, NH, N-CH3or N-benzyl;

R(17) implies (C1-C8)-alkyl;

u means zero or 1;

u2 means zero or 1;

v means zero, 1, 2, 3 or 4;

and the phenyl nucleus is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF3, methyl, metoxygroup, -(CH2)wNR(21)R(22), NR(18)R(19) and (C1-C9)-heteroaryl;

where

R(18) R(19), R(21) R(22) independently of one another denote (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;

w is 1, 2, 3 or 4;

moreover, a heterocycle (C1-C9)-heteroaryl not substituted or is substituted by 1-3 substituents selected from the group consisting of F, C1, CF3, methyl or metoxygroup;

R(2), R(3), R(4) and R(5) independently of one another are specified for R(1); or

R(1) and R(2) or R(2) and R(3) together mean a group-CH-CH=CH-CH-, which is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, C1, CF3, methyl, metoxygroup, -(CH2)w2NR(24)R(25) and NR(26)R(27);

where
is 1, 2, 3, or 4;

and the molecule contains at least two residue is T, at most three;

and their pharmaceutically acceptable salts

The invention relates to orthotamine benzoylpyridine formula (1), where R(1) denotes R(13)-SOmm denotes the number 2; R(13) denotes alkyl, one of the substituents R(2) and R(3) represents hydrogen; and the other CHR(30)R(31), R(30) represents-(CH2)g-(CHOH)h-(CH2)I-(CHOH)k-R(32), R(32) denotes hydrogen or methyl, g, h, I is equal to zero, k is 1, R(2) and R(3) represents-C(OH)R(33)R(34), R(31), R(33) R(34) denote hydrogen or alkyl, R(4) denotes alkyl, alkoxy, F, Cl, Br, I

The invention relates to medicine and can be used to obtain therapeutic agents with anti-ischemic activity in the prevention and treatment of ischemic heart disease

The invention relates to purine derivative of L-nucleoside of the formula (I), where R1, R2', R3' and R4- N; R2, R3and R5- HE; Z1- N; Z2selected from N and CH; Z3- NR-, -C(R)2, -S-, where R, same or different, selected from H, Br, NH2, alkyl and alkenyl; Z4selected from C=O, -NR-, -C(R)2- where R, same or different, selected from H and Br; Z5Is N; X is selected from H, HE, SH, -SNH2, -S(O)NH2, -S(O)2NH2Y from H and NH2; W is O, and Y represents NH2then Z3is not a-S-
The invention relates to medicine, in particular to gynecology

The invention relates to methods for treating diseases caused by hepatitis B virus (also known as HBV and Epstein-Barr (also known as EBV, which include the introduction of an effective amount of one or more of the active compounds disclosed here, or farmatsevticheskii acceptable derivatives or prodrugs of one of these compounds

The invention relates to new nukleotidfosfatazu derived from the remnants of lipid esters of General formula I, in which R1, R2represent a linear or branched saturated alkyl chain containing 1-20 carbon atoms; R3, R5represent hydrogen, hydroxyl group; R4represents a hydroxyl group; X represents a sulfur atom, sulfinyl or sulfonyloxy group; Y represents an oxygen atom; b is a purine and/or pyrimidine base, provided that at least one of the residues R3or R5represents hydrogen; their tautomers, their optically active forms and racemic mixtures, or their physiologically acceptable salts with inorganic and organic acids and/or bases, and also to processes for their preparation and medicines containing the above-mentioned connection

The invention relates to medicine
The invention relates to medicine, in particular to therapy, and can be used for the prevention of relapse of peptic ulcer of the duodenum

The invention relates to medicine, in particular to a gastroenterologist, and for the treatment of hypertonic-hyperkinetic forms of biliary dyskinesia in young people

The invention relates to medicine, specifically to the means of the treatment of seizures predominantly toxic etiology on the basis of anticonvulsant class of benzodiazepines sibazona
Up!